Michael P. Dube - 10 Apr 2024 Form 3 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
Principal Accounting Officer
Signature
James Basta, attorney-in-fact
Issuer symbol
NTLA
Transactions as of
10 Apr 2024
Net transactions value
$0
Form type
3
Filing time
22 Apr 2024, 16:10:07 UTC
Next filing
03 Jul 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NTLA Common Stock 31,223 10 Apr 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes (i) a grant of 18,976 restricted stock units and (ii) a grant of 12,247 restricted stock units, each representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

Remarks:

Exhibit 24.1 - Power of Attorney.